SCHEMBL508783

SCHEMBL508783

CC(C)c1ccc(CN(C(=O)NNF)c2c(Cl)ccc3c2CCNCC3)cc1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 8/20 0.36
HTR2A P28223 5/20 0.36
HTR2C P28335 5/20 0.36
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ACACB O00763 1/20 0.32
C5AR1 P21730 2/20 0.32
GPR183 P32249 1/20 0.31
ADGRF1 Q5T601 1/20 0.31
GPR65 Q8IYL9 1/20 0.31
PNMT P11086 2/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL507314 0.68 LMNA (0.48) HTR2BHTR2AHTR2CMEN1KMT2A
Succinic Acid SCHEMBL507602 0.66 HTR2C (0.42) HTR2BHTR2AHTR2CPNMTADRA2A
Succinic Acid SCHEMBL507771 0.65 HTR2B (0.40) HTR2BHTR2AHTR2CPNMTADRA2A
Succinic Acid SCHEMBL507540 0.65 LMNA (0.45) HTR2BHTR2AHTR2CMEN1KMT2A
SCHEMBL10228225 0.65 HTR2B (0.48) HTR2BHTR2AHTR2CPNMTADRA2A
SCHEMBL10228224 0.63 HTR2B (0.48) HTR2BHTR2AHTR2CMEN1KMT2A
Succinic Acid SCHEMBL2588197 0.63 HTR2B (0.35) HTR2BHTR2AHTR2CMEN1KMT2A
SCHEMBL13685367 0.63 HTR2B (0.37) HTR2BHTR2AHTR2CMEN1KMT2A
Succinic Acid SCHEMBL508327 0.62 HTR2B (0.36) HTR2BHTR2AHTR2CMEN1KMT2A
SCHEMBL2588552 0.62 HTR2B (0.41) HTR2BHTR2AHTR2CPNMTADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A HTR2B 12/4885HTR2A 4/4885HTR2C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.